Pluristem Therapeutics Inc. (NASDAQ: PSTI) has continued its impressive bullish trajectory for the last 14 days. Although growth on Thursday was a modest 2.75%, it was during pre-market that traders were truly taken aback. The stock ballooned up by a whopping 4.28%. Retail traders, as well as longer-term investors, continue to monitor movement, with ears open to any news surrounding Pluristem Therapeutics.
Updates on PSTI Ambitions for the Year
Potential investors are keenly eyeing the prospects of Pluristem Therapeutics. Making the rounds amongst wider discourse this week, The Israeli developer of cell-therapy-based products has big ambitions for this year. Recent developments that have been emerging have primarily caused the recent hysteria around PSTI, leading to heightened chatter. The hype surrounding PSTI stock can be traced back to Tuesday when CEO Yaky Yanay briefed shareholders on crucial updates. These had included the following breakthroughs:
- Partnership with Israeli food-producing giant, Tnuva for the development of cultured meat solutions. With Pluristem’s vast experience and expertise around stem cell development, there is clear potential for global leadership within this domain. This emerging industry holds immense growth potential for PSTI.
- The company has a strong pipeline of innovative and revolutionary candidates for stem-cell treatment approaching actualization this year. This includes a phase III trial on muscle regeneration, along with a phase I trial relating to hematopoietic cell transplantation. The company is further optimistic about next-gen biomedical solutions, such as induction and CRISPR. Each constituent initiative within the company’s impressive portfolio of projects could result in breakthroughs that could redefine the biopharmaceutical realm. Pluristem could likely become a world leader in these cutting-edge domains, shortly.
- An initiative to expand commercial capabilities in the coming years to diversify the application of the company’s stem cell products. The company plans on expanding its collaboration with different industries to work towards this strategic vision. The hiring of Chief Commercial Officer, Nimrod Bar Zvi, further reinforces this strategic goal.
Conclusion
Each of these critical updates emphasizes the growth potential that PSTI is yet to realize. The trade figures about the PSTI stock had gone on to reflect this sudden optimism. Investors are eagerly watching the magnitude of this growth trend, which is evident by its sheer trade volume.
